Reĭzis A R, Nurmukhametova E A
Ter Arkh. 1998;70(10):48-51.
To assess benefit for children with malignant blood disease (MBD) of the hepatoprotector heptral.
67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered.
Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent.
Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.
评估保肝药物阿得福韦酯对患有恶性血液病（MBD）儿童的益处。
对67名年龄在3至14岁的血液恶性肿瘤患儿进行了检查（其中53名患有急性淋巴细胞白血病）。39名患者进入研究组（其中25名患有乙型或丙型肝炎），28名作为对照组。最初，静脉注射阿得福韦酯（14天），然后口服（16至30天）。记录转氨酶活性以及因肝毒性导致的多药化疗方案违规次数。
阿得福韦酯的使用导致谷丙转氨酶（AlAT）和谷草转氨酶（AsAT）活性受到抑制，尤其是在未感染患者中。方案偏差变得不那么频繁。
阿得福韦酯在毒性、病毒性和混合性肝损伤中是一种有效的保肝药物。
